| abstract |
Glucopyranosyloxypyrazole Derivative of Formula I wherein R.sup.1.n. is H or C 1-6 1-6 alkyl; one of the Q.sup.1.n symbol. and T.sup.1.n. is a group of formula A while the other is C 1-6 1-6 alkyl or halogen (C 1-6 1-6 alkyl); and R.sup.2.n. is H, C.sub.1-6nalkyl, C.sub.1-6n.alkoxy, C.sub.1-6.n.alkylthio, halogen (C.sub.1-6.n alkyl) having 1 to 3 identical or different halogen atoms, or a halogen atom or a pharmaceutically acceptable salt thereof. A pharmaceutical composition comprising the derivative and its use as an inhibitor of human SGLT2 or for preventing or treating diabetes or obesity. The benzylpyrazole intermediate of formula Va, wherein R.sup.2 is C.sub.1-6n.alkyl, C.sub.1-6.n.alkoxy, C.sub.1-6.n. alkylthio, halogen (C.sub.1-6n.alkyl) having 1 to 3 identical or different halogen atoms, or a halogen atom and R.sup.3. is C 1-6 alkyl, or a salt thereof. |